Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade

Douglas B. Johnson(Vanderbilt University Medical Center), Christine M. Lovly(Dana-Farber Cancer Institute), Ryan J. Sullivan(Dana-Farber Cancer Institute), Justin Cates(Vanderbilt University Medical Center), Yuting He(Harbin Medical University), Harlan Robins(Adaptive Biotechnologies (United States)), Yaomin Xu(Vanderbilt University Medical Center), James Sun(GlobalFoundries (United States)), Matthew J. Rioth(Vanderbilt University Medical Center), Erik Yusko(Adaptive Biotechnologies (United States)), Dennie T. Frederick(Broad Institute), Igor Puzanov(Roswell Park Comprehensive Cancer Center), Zachary R. Chalmers(Northwestern University), Sohail Balasubramanian(GlobalFoundries (United States)), Yu Shyr(Vanderbilt University), Riley Ennis(GlobalFoundries (United States)), Garrett M. Frampton(Tech Foundation), Jeffrey A. Sosman(Robert H. Lurie Comprehensive Cancer Center of Northwestern University), Xingyi Guo(Vanderbilt University Medical Center), Jeffrey S. Ross(Unknown), Siraj M. Ali(UPMC Hillman Cancer Center), Justin M. Balko(Vanderbilt University Medical Center), Catherine Sanders(Adaptive Biotechnologies (United States)), Vincent A. Miller(Universidad San Carlos), Joel Greenbowe(GlobalFoundries (United States)), Philip J. Stephens(United States Department of the Navy), David Fabrizio(Foundation Medicine (United States))
Cancer Immunology Research
September 26, 2016
Cited by 493


Related Papers